During the last session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s traded shares were 0.43 million, with the beta value of the company hitting 1.74. At the end of the trading day, the stock’s price was $1.82, reflecting an intraday loss of -5.70% or -$0.11. The 52-week high for the ZNTL share is $16.26, that puts it down -793.41 from that peak though still a striking 11.54% gain since the share price plummeted to a 52-week low of $1.61. The company’s market capitalization is $129.70M, and the average trade volume was 1.90 million shares over the past three months.
Zentalis Pharmaceuticals Inc (ZNTL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. ZNTL has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.68.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Zentalis Pharmaceuticals Inc (ZNTL) registered a -5.70% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.70% in intraday trading to $1.82, hitting a weekly high. The stock’s 5-day price performance is -12.08%, and it has moved by -14.95% in 30 days. Based on these gigs, the overall price performance for the year is -87.24%.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 81.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $55 respectively. As a result, ZNTL is trading at a discount of -2921.98% off the target high and -119.78% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -50.05%. While earnings are projected to return 44.92% in 2025, the next five years will return 18.52% per annum.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 8.68 million shares, is of FMR LLC’s that is approximately 12.2383% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $35.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Zentalis Pharmaceuticals Inc (ZNTL) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 2.83 shares. This amounts to just over 3.96 percent of the company’s overall shares, with a $5.14 million market value. The same data shows that the other fund manager holds slightly less at 1.89, or about 2.66% of the stock, which is worth about $3.45 million.
